Pediatric obesity and perioperative medicine

Christian Mpody1, Kwaku Owusu-Bediako, Vidya T Raman

  • 1Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.

Insights

Childhood obesity presents significant perioperative challenges, impacting anesthetic management and patient safety. Further research is crucial to mitigate risks for obese children undergoing surgery.

Area of Science:

  • Pediatric Anesthesiology
  • Public Health
  • Obesity Medicine

Background:

  • Childhood obesity is a global health crisis with substantial economic implications.
  • Obesity significantly complicates perioperative care, increasing patient risks.
  • Limited research exists on the specific perioperative ramifications of childhood obesity.

Purpose of the Study:

  • To update on challenges in defining and classifying obesity in perioperative settings.
  • To review perioperative implications, including positioning, vascular access, and anesthetic dosing for obese children.
  • To identify research gaps and advocate for increased research in perioperative childhood obesity.

Main Methods:

  • Literature review of perioperative challenges in childhood obesity.
  • Analysis of current understanding of anesthetic and surgical risks.
  • Identification of knowledge gaps and future research directions.

Main Results:

  • Obesity definition and classification pose unique perioperative challenges.
  • Patient positioning, vascular access, and medication dosing require specific considerations for obese children.
  • There is a critical need for enhanced understanding and research into perioperative risks and management strategies.

Conclusions:

  • Anesthesiologists and surgeons face a growing number of obese children with high perioperative complication risks.
  • Improved risk assessment, mitigation, and patient management are essential.
  • Urgent call for action to address research gaps in perioperative childhood obesity.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
44
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
65
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
56
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
44
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
872
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
57